<?xml version="1.0" encoding="UTF-8"?>
<table xmlns="http://www.w3.org/1999/xhtml">
 <thead>
  <caption>PMC6617838</caption>
  <tr>
   <th>label</th>
   <th>caption</th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td>Figure 1</td>
   <td>Solubility of MTX in crude oil ( A) and 10% surfactant solut ... </td>
  </tr>
  <tr>
   <td>Figure 2</td>
   <td>Formulation of liquid SMEDDS. Pseudo-ternary phase diagram ( ... </td>
  </tr>
  <tr>
   <td>Figure 3</td>
   <td>SEM images of ( A) MTX powder (x2,000), ( B) calcium silicat ... </td>
  </tr>
  <tr>
   <td>Figure 4</td>
   <td>DSC curves for MTX powder ( A), calcium silicate ( B), physi ... </td>
  </tr>
  <tr>
   <td>Figure 5</td>
   <td>PXRD curves for MTX powder ( A), calcium silicate ( B), phys ... </td>
  </tr>
  <tr>
   <td>Figure 6</td>
   <td>FTIR bands for MTX powder ( A), calcium silicate ( B), physi ... </td>
  </tr>
  <tr>
   <td>Figure 7</td>
   <td>Drug solubility ( A) and dissolution profiles ( B) of MTX po ... </td>
  </tr>
  <tr>
   <td>Figure 8</td>
   <td>Mean plasma concentrationâ€“time profiles of MTX after oral ad ... </td>
  </tr>
  <tr>
   <td>Figure 9</td>
   <td>Residual concentration of MTX after exposure to photolytic c ... </td>
  </tr>
 </tbody>
</table>
